Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF

Summary

This phase I trial studies how well fluorine F 18 fluorthanatrace positron emission tomography (PET)/computed tomography (CT) works in patients with solid tumors. Fluorine F 18 fluorthanatrace is a radioactive tracer, a type of imaging agent that is labeled with a radioactive tag and injected into the body to help with imaging scans. PET/CT uses a scanner to make detailed, computerized pictures of areas inside the body. PET/CT with Fluorine F 18 fluorthanatrace may allow more tumor cells to be found in patients with ovarian, fallopian tube, or primary peritoneal cancer.

Conditions

• Breast Carcinoma
• Fallopian Tube Carcinoma
• Ovarian Carcinoma
• Primary Peritoneal Carcinoma
• Recurrent Fallopian Tube Carcinoma
• Recurrent Ovarian Carcinoma
• Recurrent Primary Peritoneal Carcinoma
• Solid Neoplasm

Interventions

PROCEDURE

Computed Tomography

Undergo FDG PET/CT

PROCEDURE

Computed Tomography

Undergo \[18F\]FTT PET/CT

RADIATION

Fludeoxyglucose F-18

Given IV

RADIATION

Fluorine F 18 Fluorthanatrace

Given IV

PROCEDURE

Positron Emission Tomography

Undergo FDG PET/CT

PROCEDURE

Positron Emission Tomography

Undergo \[18F\]FTT PET/CT

Sponsors & Collaborators

• National Cancer Institute (NCI)

  collaborator NIH

• M.D. Anderson Cancer Center

  lead OTHER

Principal Investigators

• Lilie L Lin · M.D. Anderson Cancer Center

Study Design

Allocation

NA

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Sex

FEMALE

Healthy Volunteers

No

Timeline & Regulatory

Start

2018-12-18

Primary Completion

2027-06-30

Completion

2027-06-30

FDA Drug

Yes

Countries

• United States

Study Locations